Status:
RECRUITING
Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.
Lead Sponsor:
Centre Georges Francois Leclerc
Conditions:
All Types of Metastatic Solid Malignancy
1st-line Treatment
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Currently, the EXOMA2 study (NCT04614480) offers earlier and more comprehensive exome analysis in the management of cancer patients than EXOMA. Based on the active EXOMA2 patient file, the INFOGene st...
Detailed Description
Currently, the EXOMA2 study (NCT04614480) offers earlier and more comprehensive exome analysis in the management of cancer patients than EXOMA. Based on the active EXOMA2 patient file, the INFOGene st...
Eligibility Criteria
Inclusion
- Patient identified for inclusion in the EXOMA 2 study (exome analysis request)
- Available to receive different types of information
- Fluent in French
- No prior oncogenetic consultation
- Having been informed of the objectives of the study and having given written non-objection to participate in the INFOGene study
- Authorizing audio recording of consultations and interviews
Exclusion
- Patient who refused to participate in the EXOMA2 study (for phase 3 patients only)
- Has a psychiatric, cognitive or neurological disorder that makes participation impossible
- Working in the field of genetics
Key Trial Info
Start Date :
September 19 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2026
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06550687
Start Date
September 19 2024
End Date
November 1 2026
Last Update
February 18 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Georges-François Leclerc
Dijon, France, 21000
2
CHU François Mitterand
Dijon, France, 21000